281 related articles for article (PubMed ID: 17416533)
1. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
Ishihara T; Seki N; Hirayama F; Orita M; Koshio H; Taniuchi Y; Sakai-Moritani Y; Iwatsuki Y; Kaku S; Kawasaki T; Matsumoto Y; Tsukamoto S
Bioorg Med Chem; 2007 Jun; 15(12):4175-92. PubMed ID: 17416533
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
Koshio H; Hirayama F; Ishihara T; Shiraki R; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Kaku S; Katayama N; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2005 Feb; 13(4):1305-23. PubMed ID: 15670939
[TBL] [Abstract][Full Text] [Related]
3. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.
Koshio H; Hirayama F; Ishihara T; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2004 May; 12(9):2179-91. PubMed ID: 15080918
[TBL] [Abstract][Full Text] [Related]
6. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.
Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H
Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303
[TBL] [Abstract][Full Text] [Related]
7. Amino(methyl) pyrrolidines as novel scaffolds for factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Han W; Hu Z; Stein PD; Wang Y; Kennedy LJ; O'Connor SP; Ahmad S; Liu EC; Seiler SM; Lam PY; Robl JA; Macor JE; Atwal KS; Zahler R
Bioorg Med Chem Lett; 2007 Nov; 17(21):5952-8. PubMed ID: 17855089
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor.
Mochizuki A; Nakamoto Y; Naito H; Uoto K; Ohta T
Bioorg Med Chem Lett; 2008 Jan; 18(2):782-7. PubMed ID: 18039572
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.
Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Uchida I; Aisaka K; Hase Y; Katoh S; Cho H
Bioorg Med Chem Lett; 2005 Jan; 15(1):185-9. PubMed ID: 15582437
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P
Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211
[TBL] [Abstract][Full Text] [Related]
13. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
Shi Y; O'Connor SP; Sitkoff D; Zhang J; Shi M; Bisaha SN; Wang Y; Li C; Ruan Z; Lawrence RM; Klei HE; Kish K; Liu EC; Seiler SM; Schweizer L; Steinbacher TE; Schumacher WA; Robl JA; Macor JE; Atwal KS; Stein PD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7516-21. PubMed ID: 22041058
[TBL] [Abstract][Full Text] [Related]
14. Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa.
Lopopolo G; Fiorella F; de Candia M; Nicolotti O; Martel S; Carrupt PA; Altomare C
Eur J Pharm Sci; 2011 Feb; 42(3):180-91. PubMed ID: 21112391
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
Ueno H; Katoh S; Yokota K; Hoshi J; Hayashi M; Uchida I; Aisaka K; Hase Y; Cho H
Bioorg Med Chem Lett; 2004 Aug; 14(16):4281-6. PubMed ID: 15261287
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydro-isoquinoline-based factor Xa inhibitors.
Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
[TBL] [Abstract][Full Text] [Related]
18. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
Young RJ; Borthwick AD; Brown D; Burns-Kurtis CL; Campbell M; Chan C; Charbaut M; Chung CW; Convery MA; Kelly HA; Paul King N; Kleanthous S; Mason AM; Pateman AJ; Patikis AN; Pinto IL; Pollard DR; Senger S; Shah GP; Toomey JR; Watson NS; Weston HE
Bioorg Med Chem Lett; 2008 Jan; 18(1):23-7. PubMed ID: 18054228
[TBL] [Abstract][Full Text] [Related]
19. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
Ewing WR; Becker MR; Manetta VE; Davis RS; Pauls HW; Mason H; Choi-Sledeski YM; Green D; Cha D; Spada AP; Cheney DL; Mason JS; Maignan S; Guilloteau JP; Brown K; Colussi D; Bentley R; Bostwick J; Kasiewski CJ; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1999 Sep; 42(18):3557-71. PubMed ID: 10479288
[TBL] [Abstract][Full Text] [Related]
20. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
